Takeda Pharmaceutical's key products' sales values FY 2022
In fiscal year 2022, the sales value of ENTYVIO produced by Takeda Pharmaceutical Co., Ltd. accounted for approximately 702.7 billion Japanese yen, marking the highest sales value among the company's key products. The sales value of immunoglobulin amounted to 522.2 billion yen in fiscal 2022, marking the second-highest sales value.